TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies

Figure 1 Surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptors on Huh7 and Hep-G2 cells. Flow cytometric analysis of TRAIL receptors was performed using monoclonal mouse IgG1, anti-TRAIL-R1, -R2, -R3, -R4 antibodies and secondary FITC-conjugated polyclonal goat anti mouse-IgG1 antibodies. Unspecific mouse IgG1 antibodies were used as isotype control. Receptor surface expression was analyzed in untreated Huh7 and Hep-G2 cells (A) and 12 h after treatment with 100 ng/mL rec. TRAIL + 1 μg/mL Enhancer (B), 50 μg/mL 5-fluorouracil (5-FU) (C) and 0.5 μmol/L doxorubicin (D). Diagrams are representative of at least two independent experiments. Doxo: Doxorubicin.